Talisman Therapeutics

Talisman Therapeutics is a drug discovery company specialising in human induced pluripotent stem cell (iPSC) models of neurodegenerative disease.

The company operates both an internal discovery pipeline, focused on Alzheimer's disease targets including lysosome biology, pathogenic protein reduction and microglial health, and an external collaboration programme.

Talisman's iPSC-derived neural cell models are designed to improve the relevance and predictivity of early-stage compound screening.